Injective doubles down on deflation — but traders stay cautious
Injective’s community has approved an ambitious tokenomics overhaul designed to accelerate INJ’s path to becoming a highly deflationary asset — yet market reaction so far has been muted.
What passed
- The “supply squeeze” proposal (IIP-617), first floated on Jan. 16, won near-unanimous support, with 99.89% of votes in favor.
- The upgrade doubles the protocol’s total supply reduction rate — a 100% increase to the structural mechanisms that shrink circulating INJ.
- As part of the change, emissions will be cut in half and buybacks will be increased to more aggressively remove tokens from circulation.
Why it matters
- Injective launched with a total supply of 100 million INJ; INJ is the ecosystem’s governance token.
- The chain’s inflation (emissions paid as staking rewards) is dynamic and ranges roughly 5–10%, depending on the staking ratio (target cited: 85%).
- Historically, Injective has used protocol fees to fund buybacks; over 6.8 million INJ have already been burned via that program. The new plan amplifies that deflationary push by combining lower emissions with larger buybacks.
Market context and skepticism
- Token buyback programs are a contested tool in crypto. Proponents call them a way to concentrate value for holders; critics argue buybacks can be inefficient if they don’t trigger sustained price demand. Examples of mixed outcomes include projects such as Hyperliquid (HYPE), Pump.fun and Jupiter (JUP), the latter explicitly warning buybacks are a poor use of resources absent price appreciation.
- Whether Injective’s dual approach (reduced emissions + bigger buybacks) will translate into lasting price gains remains uncertain.
Price and trading data
- INJ ticked up about 4% immediately after the announcement but later pared gains amid broader market weakness. Bitcoin slid toward $90,000 following reports that U.S. President Donald Trump announced tariffs on Europe, a headline that weighed on risk assets.
- INJ briefly sank below $5 and revisited December lows near $4.40; technical observers note a potential retest of support around $4.42 if selling pressure continues.
- On derivatives markets, demand signals have been soft: Futures Cumulative Volume Delta (CVD), a measure of net directional demand in futures, turned more negative from Jan. 15 and stayed lower despite the tokenomics upgrade.
- Open Interest has remained largely unchanged near $25 million, indicating derivatives positioning hasn’t materially increased in response to the proposal.
Bottom line
Injective’s community has committed to a bolder deflationary roadmap that halves emissions and ramps up buybacks. But early on, macro forces and weak futures demand have blunted any sustained price reaction. Whether the “supply squeeze” will ultimately deliver the intended value accrual for INJ will depend on market participation and whether buybacks can trigger renewed buying interest.
Disclaimer: This article is informational and not investment advice. Cryptocurrency trading carries significant risk; do your own research before making investment decisions. Sources: Injective statement, TradingView, Velo.
Read more AI-generated news on: undefined/news
